AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04153396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The Control group
Description: The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
Study NCT04941287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04941287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06404411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned interventions
Description: Combined aerobic endurance exercise in the control group: individualized exercise prescription, including 5-10 minutes of pre-exercise dynamic stretching and warm-up, 10-30 minutes of formal aerobic exercise, and 5-10 minutes of post-exercise stretching, formal aerobic exercise using a power bike starting from low-intensity and gradually increasing to medium-high-intensity, with a frequency of five times per week.
Study NCT06404411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation
Description: Adoption of conventional rehabilitation, drug therapy, enhanced nutritional support and other conventional treatment
Study NCT06404411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: Adoption of conventional rehabilitation, drug therapy, enhanced nutritional support and other conventional treatment
Study NCT06452160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGC515
Description: Capsules for oral administration
Study NCT05564832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine 1.25% Eye drop
Description: One millimeter of pilocarpine eye drop (Bakhtarbiochemistry Company, Iran) contains pilocarpine hydrochloride 1.25% (12.5 mg) as an active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. The medication preservative is 0.0075% benzalkonium chloride. Inactive ingredients in the ophthalmic are boric acid, sodium citrate dihydrate, sodium chloride, purified water. Another pilocarpine eye drop was Vuity® (1.25% pilocarpine; Allergan company) contains the active intergradients of pilocarpine hydrochloride 1.25% (12.5 mg/mL), equivalent to 1.06% (10.6 mg/mL) pilocarpine free-base and the preservative agents was 0.0075% benzalkonium chloride.
Study NCT05251103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: time-restricted feeding trial
Description: The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.
Study NCT05389410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO 7
Description: Participant will receive 7 days of NPWT following revision hip or revision knee surgery.
Study NCT05389410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO 7
Description: Participant will receive 7 days of NPWT following revision hip or revision knee surgery.
Study NCT05389410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO 14
Description: Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
Study NCT05389410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO 14
Description: Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
Study NCT06361498 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound Imaging
Description: Participant will receive ultrasound imaging to evaluate the replaced G-tube placement.
Study NCT05166265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcutaneous bone conduction hearing system
Description: The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.
Study NCT04245566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization (PAE)
Description: Prostatic artery embolization will be performed under local anesthesia according to well established and standardized techniques.
Study NCT04245566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacotherapy
Description: Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations
Study NCT05773183 — intervention group
Intervention type: DRUG
Intervention: Testosterone
Description: In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
Study NCT05773183 — intervention group
Intervention type: DRUG
Intervention: GnRH
Description: 20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
Study NCT05561400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 5x5 saline-soaked sponge electrodes will be used with the cathode placed over the right cerebellar hemisphere; 1cm under and 4cm lateral of the inion targeting lobule VII and the anode will be placed on the right shoulder. The electrode placement will be the same across both conditions.
Study NCT05561400 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sham tDCS to the right cerebellum
Study NCT04604704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone at 4.5 mg/day
Study NCT04604704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAD+
Description: NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.
Study NCT04941287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04941287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT04941287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT04941287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04941287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlilumab
Description: Given IV
Study NCT03550352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg)
Description: Participants will start by taking 1 capsule twice daily for 1 week (5 mg THC/5 mg CBD) and increase the number of capsules as tolerated to a maximum of 6 capsules taken throughout the day by weeks 5-12 (15 mg THC/15 mg CBD total per day).
Study NCT03550352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TN-C200M2 oral capsules (CBD 200 mg)
Description: Participants will start by taking 1 capsule once daily for 1 week (200 mg CBD) and increase the number of capsules as tolerated to a maximum of 4 capsules taken throughout the day by weeks 5-12 (800 mg CBD total).
Study NCT06141070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard systemic therapy + radiotherapy
Description: Combined systemic therapy + radiation
Study NCT06141070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard systemic therapy
Description: Chemoimmunotherapy or immunotherapy
Study NCT05557786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation
Description: Cerebellar Transcranial Alternating Current Stimulation（tACS）
Study NCT05557786 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation
Description: Cerebellar Transcranial Alternating Current Stimulation（tACS）
Study NCT05596708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.
Study NCT05628636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-01-VA
Description: formulation of tricaprilin
Study NCT04908826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green (ICG) administration
Description: Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.
Study NCT06330870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WGS/TME evaluation
Description: WGS/TME evaluation with blood and brain metastasis tissue during brain metastasis curative surgery
Study NCT05456607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
Study NCT05456607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Depression
Description: Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
Study NCT05456607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood Monitoring
Description: The mood monitoring intervention is based on mood tracking principles in broader mood management interventions, but without any psychoeducational content or cognitive-behavioral exercises. Instead, participants will get access to a mobile optimized web app that allows users to enter their mood, tag related events, and view trends over time to raise awareness of how activities influence certain mood states.
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: TCI
Description: Temperament and character inventory
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: BPI
Description: Brief Pain Inventory
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: CPAQ-8
Description: Chronic Pain Acceptance Questionnaire-8
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: SF-MPQ
Description: short-form McGill Pain Questionnaire
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: King's Parkinson's Disease Pain Scale (KPPS)
Description: King's Parkinson's Disease Pain Scale
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: Hospital Anxiety and Depression scale (HAD) questionary
Description: Hospital Anxiety and Depression scale
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: PCS
Description: Pain Catastrophism Scale
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: ORT
Description: Opioid Risk Tool
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: Social Support Questionnaire (SSQ6)
Description: Social Support Questionnaire (SSQ6) (score of availability and score of satisfaction)
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: IPQ-R
Description: Illness Perception Questionnaire Revised
Study NCT05713500 — intervention group
Intervention type: OTHER
Intervention: WCC-R
Description: Ways of Coping Checklist Revised
Study NCT04983121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
Description: The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
Study NCT06375408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial alternating electrical stimulation
Description: The patients in the intervention group were treated with real tACS produced by Nexalin company. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
Study NCT06375408 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial alternating electrical stimulation
Description: The patients in the control group were treated with sham tACS produced by Nexalin company. The fake tACS does not emit current, so it does not stimulate the cerebral cortex. The appearance, button, electrode, and quality of the fake tACS are exactly the same as those of the real tACS in patients' senses. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
Study NCT05324735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.
Study NCT05324735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will receive placebo (orally ingested) twice a day for 12 weeks.
Study NCT04465188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Encircling scleral buckle surgical procedure
Description: Encircling scleral buckle surgical procedure under general anesthesia
Study NCT05123937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BOBATH technique
Description: In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
Study NCT05123937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task training
Description: In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
Study NCT05292742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib+Trastuzumab+Capecitabine
Description: Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine
Study NCT05292742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab+Pertuzumab/Trastuzumab
Description: Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose
Study NCT05387902 — intervention group
Intervention type: DEVICE
Intervention: Extracorporeal Membrane Oxygenation
Description: Patients with high-risk PCI receive mechanical circulatory support with ECMO.
Study NCT01966081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Study NCT01966081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tissue samples from abdominal subcutaneous adipose
Study NCT05290181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A support program with pilates exercise and whatsapp text message
Description: Female students in the intervention group will be given online pilates exercises 2 days a week for 8 weeks. Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises will be provided. The exercises will be performed in the company of a research physiotherapist who has The Australian Physiotherapy \& Pilates InstituteMatwork Level 1 (APPI) certificate. 3 days a week, individual short messages will be sent to the smartphones of female students via the Whatsapp application. General information about PMS will be sent in the first week, and motivational messages about lifestyle will be sent in the following weeks. Short message contents will be prepared by researchers in line with the literature and expert opinion will be taken. When the support program ends, PMSS will be applied to female students in the intervention group.
Study NCT06373575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung and inferior vena cava ultrasound guidance
Description: The lung and inferior vena cava ultrasound will be utilized as guidance for the development of a dialysis prescription for prolonged hemodialysis.
Study NCT06373575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protocol guidance
Description: Fluid removal using conventional protocol including blood pressure and physical examination
Study NCT05282654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePRO Application
Description: The intervention consists of a patient portal, EHR-integrated web-app to communicate risk of post-discharge adverse events using patient-reported outcome questionnaires, discharge preparation checklist during hospitalization. After discharge, the intervention will provide real-time symptom monitoring using ePROs and facilitate communication with clinicians based on prediction model-informed ePRO score trends exceeding escalation thresholds.
Study NCT05903365 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Additional blood samples at J100, M6, M12, M24
Study NCT06111911 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV Diagnostic Kit (Bio Farma)
Description: Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.
Study NCT06073249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular vagus stimulation
Description: Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular or carotid artery. It is also used to treat various disorders such as epilepsy, pain and headache. This device stimulates the auricular branch of the vagus nerve non-invasively without any procedure. As a result, it has been found that the pain threshold increases and mechanical pain sensitivity decreases.
Study NCT06073249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tibial Nerve Stimulation
Description: The sacral plexus provides innervation of the perineal muscle. Its branches (lumbar 4-5 and sacral 1-3) merge to form the nervus ischiadicus, which then divides into two branches. The thick branch of the nervus ischiadicus is the nervus tibialis (lumbar 4-5 and sacral 1-3) and the thin branch is the nervus peroneus communis (lumbar 4-5 and sacral 1-2).